GLP-1 agonists
Repurposing GLP-1 receptor agonists (exenatide, lixisenatide, semaglutide) as potential disease-modifying treatments.
State of the art
No update yet for GLP-1 agonists. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
No reader summaries on this topic yet.